Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study.
Stephen Lam ChanTerry Cheuk-Fung YipVincent Wai-Sun WongYee-Kit TseBecky Wing-Yan YuenHester Wing-Sum LukRashid Nok-Shun LuiHenry Lik-Yuen ChanTony Shu-Kam MokGrace Lai-Hung WongPublished in: Cancer medicine (2020)
Hepatic AEs occur in more than half of patients receiving ICIs for cancer treatment, with approximately 15% being grade 3-4 AEs. Occurrence of hepatic AEs is associated with worse prognosis.
Keyphrases